Journal of Dermatological Treatment最新文献_第4页

Multiple COVID reinfections in a vaccinated psoriatic patient receiving adalimumab. 一名接受阿达木单抗治疗的接种过疫苗的银屑病患者出现多次 COVID 再感染。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2023-12-01 Epub Date: 2022-11-22 DOI: 10.1080/09546634.2022.2149237

Omid Zargari, Seyyede Zeinab Azimi

{"title":"Multiple COVID reinfections in a vaccinated psoriatic patient receiving adalimumab.","authors":"Omid Zargari, Seyyede Zeinab Azimi","doi":"10.1080/09546634.2022.2149237","DOIUrl":"10.1080/09546634.2022.2149237","url":null,"abstract":"Currently, psoriasis patients are advised to follow their standard therapeutic regimen, and are advised to be vaccinated against Covid-19. However, the data about the antibody responses, induced by the various kinds of SARS-CoV-2 vaccines in psoriasis patients who require systemic immunosuppressive treatment is scant. In this case report, we describe antibody responses induced by COVID-19 vaccine, in a 26-year-old male patient with psoriasis being treated with anti-TNF biotherapy, adalimumab biosimilar every two weeks. The patient was vaccinated against COVID-19, according to the national protocol. He experienced three episodes of symptomatic COVID-19. His first and second exposures did not result in antibody production. After the third episode of COVID-19, The SARS-CoV-2 anti-spike antibody (IgG) was more than 100 Ru/mL (ELISA; ≥8 Ru/mL is considered positive), and SARS-CoV-2 neutralizing antibody (total) was more than 40 micg/mL (ELISA; ≥2.5 micg/mL is considered positive). This is the first case with weak antibody response to vaccination and multiple episodes of COVID infection in a psoriatic patient with adalimumab biosimilar. However, we cannot assume causality due to the treatment.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":" ","pages":"2149237"},"PeriodicalIF":2.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40705784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparing the odds of reported depression in psoriasis patients on systemic therapy: a cross-sectional analysis of postmarketing data. 比较接受系统治疗的银屑病患者报告抑郁的几率：上市后数据的横断面分析。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2023-12-01 Epub Date: 2023-01-19 DOI: 10.1080/09546634.2022.2152272

Samuel Yeroushalmi, Mimi Chung, Erin Bartholomew, Marwa Hakimi, John Koo

{"title":"Comparing the odds of reported depression in psoriasis patients on systemic therapy: a cross-sectional analysis of postmarketing data.","authors":"Samuel Yeroushalmi, Mimi Chung, Erin Bartholomew, Marwa Hakimi, John Koo","doi":"10.1080/09546634.2022.2152272","DOIUrl":"10.1080/09546634.2022.2152272","url":null,"abstract":"Patients with psoriasis are more likely to experience depression and suicidality compared to non-psoriatic patients, though systemic therapies have been shown to improve depressive symptoms. It is unclear whether or not biologic or oral agents are more effective at improving such depressive symptoms in psoriasis patients, however. We aimed to determine an estimate of the odds of incident depression in psoriasis patients on different systemic therapies by performing a cross-sectional analysis of postmarketing data. The reporting odds ratio (ROR) for 15 different systemic agents was calculated using reports from the Food and Drug Administration Adverse Events Reporting System (FAERS). After excluding brodalumab and apremilast due to high risk of reporting bias, we found oral agents were associated with a significantly higher ROR of depression compared to biologics (OR = 2.42, 95% confidence interval: 1.93-3.04). These results suggest biologics may be more effective at reducing incident depression than oral agents. Future controlled trials are needed to confirm these findings.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":" ","pages":"2152272"},"PeriodicalIF":2.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35260488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful treatment of hereditary hypotrichosis simplex by platelet rich plasma injection with topical minoxidil 2. 富血小板血浆注射联合外用米诺地尔成功治疗遗传性单纯性毛发减少症 2.

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2023-12-01 Epub Date: 2023-03-02 DOI: 10.1080/09546634.2023.2169575

Wafaa M Ramadan, Arwa M Hassan, Esraa E El-Hawary, Nesrin S Gomaa

引用次数: 0

Real-life effectiveness and safety of dupilumab in adolescents with atopic dermatitis: a 52-week single-center retrospective study. dupilumab治疗青少年特应性皮炎的有效性和安全性:一项52周的单中心回顾性研究

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2023-04-06 DOI: 10.1080/09546634.2023.2200867

Luigi Gargiulo, Carlo Alberto Vignoli, Luciano Ibba, Andrea Cortese, Mario Valenti, Antonio Costanzo, Alessandra Narcisi

引用次数: 1

Does hospitalization, independent of other treatment, improve severe chronic skin conditions? 独立于其他治疗的住院治疗是否能改善严重的慢性皮肤病?

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2023-01-25 DOI: 10.1080/09546634.2023.2173515

Diem-Phuong D Dao, Caitlin G Purvis, Steven R Feldman

引用次数: 0

When should systemic biologic therapy for psoriasis be discontinued? 银屑病的全身生物治疗何时应该停止?

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2023-01-25 DOI: 10.1080/09546634.2023.2173516

Diem-Phuong D Dao, Jessica N Pixley, Steven R Feldman

引用次数: 0

Efficacy and safety of stromal vascular fraction on scar revision surgery: a prospective study. 基质血管分数在瘢痕修复手术中的有效性和安全性:一项前瞻性研究。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2023-01-19 DOI: 10.1080/09546634.2023.2171260

Hyeokjae Kwon, Seokui Lee, Jiyoung Kim, Seung Han Song

{"title":"Efficacy and safety of stromal vascular fraction on scar revision surgery: a prospective study.","authors":"Hyeokjae Kwon, Seokui Lee, Jiyoung Kim, Seung Han Song","doi":"10.1080/09546634.2023.2171260","DOIUrl":"https://doi.org/10.1080/09546634.2023.2171260","url":null,"abstract":"Background: Cell-based therapies are popular in the field of reconstructive surgery. The stromal vascular fraction (SVF), comprised of mature adipocytes or blood, reportedly has a regenerative effect; however the mechanism remains unclear. This study aimed to prove the viability and effectiveness of using SVF in scar treatment.Methods: This prospective double-blind study involved 20 patients who visited an outpatient clinic for 2 years, from July 2016 to July 2018, and underwent scar revision for traumatic or surgical scars. After scar revision surgery performed by a single surgeon, patient scars were divided into experimental and control sides. The subcutaneous layer of the experimental and control sides were injected with 0.1 mL/cm of SVF and normal saline, respectively. Each side was evaluated using the Patient and Observer Scar Assessment Scale (POSAS) before and six months after the surgery.Results: Of the 20 patients who underwent scar revision surgery and SVF treatment, 4 dropped out for personal reasons. In 11 of 12 POSAS items, the experimental side showed significant improvements compared to the control side.Conclusions: Although more research is needed, autologous SVF is a valuable source of regenerative medicine that can be swiftly and inexpensively prepared from human fat tissue.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"34 1","pages":"2171260"},"PeriodicalIF":2.9,"publicationDate":"2023-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9221435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

National consensus on biologic dose reduction in psoriasis: a modified eDelphi procedure. 关于减少银屑病生物制剂剂量的全国共识：修改后的 eDelphi 程序。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2022-12-14 DOI: 10.1080/09546634.2022.2154570

L S van der Schoot, E M Baerveldt, W A van Enst, S P Menting, M M B Seyger, S L Wanders, I van Ee, A H Pieterse, J M P A van den Reek, E M G J de Jong

{"title":"National consensus on biologic dose reduction in psoriasis: a modified eDelphi procedure.","authors":"L S van der Schoot, E M Baerveldt, W A van Enst, S P Menting, M M B Seyger, S L Wanders, I van Ee, A H Pieterse, J M P A van den Reek, E M G J de Jong","doi":"10.1080/09546634.2022.2154570","DOIUrl":"10.1080/09546634.2022.2154570","url":null,"abstract":"Background: Dose reduction of biologics for psoriasis is applied in daily practice, although guidelines are lacking. Striving for clear criteria is important, as it leads to a consistent application of dose reduction.Objective: To achieve consensus on criteria for biologic dose reduction in psoriasis patients with stable and low disease activity.Methods: An online Delphi procedure (eDelphi) was conducted. Dutch dermatologists were invited to participate in a maximum of 3 voting rounds. Proposed statements were selected based on literature review and included criteria for the application of dose reduction and dosing schedules. Biologic dose reduction was defined as 'application of injection interval prolongation'. Proposed statements were rated using a 9-point Likert scale; consensus was reached when ≥70% of all voters rated 'agree' (7-9) and <15% rated 'disagree' (1-3).Results: A total of 27 dermatologists participated and reached a consensus on 15 recommendations over 2 voting rounds. Agreed statements included criteria for dose reduction eligibility, criteria for dose reduction (dis)continuation, and dosing schedules for adalimumab, etanercept, and ustekinumab. Based on the eDelphi outcomes, an algorithm fit for implementation in current practice was developed.Conclusions: Recommendations of this national consensus process can guide clinicians, and consequently their patients, toward consistent application of biologic dose reduction.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":" ","pages":"2154570"},"PeriodicalIF":2.9,"publicationDate":"2022-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10338228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systematic review of programmed cell death-1 inhibitor therapy for advanced-stage cutaneous squamous cell carcinoma in solid-organ transplant recipients. 程序性细胞死亡-1抑制剂治疗实体器官移植受者晚期皮肤鳞状细胞癌的系统评价

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2022-12-01 DOI: 10.1080/09546634.2022.2118516

Hannah L Hanania, Daniel J Lewis

{"title":"Systematic review of programmed cell death-1 inhibitor therapy for advanced-stage cutaneous squamous cell carcinoma in solid-organ transplant recipients.","authors":"Hannah L Hanania, Daniel J Lewis","doi":"10.1080/09546634.2022.2118516","DOIUrl":"https://doi.org/10.1080/09546634.2022.2118516","url":null,"abstract":"Background: Programmed cell death-1 (PD-1) inhibitors represent an effective treatment option for advanced cutaneous squamous cell carcinoma (cSCC). However, solid organ transplant (SOT) recipients with cSCC have traditionally been excluded from clinical trials.Objective: To assess the safety and efficacy of PD-1 inhibitors for stage III-IV cSCC in SOT recipients.Materials & methods: A systematic review was performed using the PubMed, EMBASE, and Scopus databases.Results: We identified 21 articles describing 33 SOT recipients (26 kidney, four liver, two lung, and one heart) with stage III-IV cSCC treated with PD-1 inhibitors. Eleven patients (33.3%) experienced allograft rejection. Of the 25 cases with iRECIST scores, twelve patients (48.0%) had a complete response (CR), eight (32.0%) showed a partial response (PR), three (12.0%) progressive disease, and two (8.0%) stable disease (SD). Including patients without available iRECIST scores, 21 patients (63.6%) showed tumor response. Eleven patients died, with six (54.5%) due to tumor progression and one (9.1%) due to allograft rejection after foregoing dialysis.Conclusion: PD-1 inhibitors demonstrate efficacy for advanced cSCC and confer a risk of allograft rejection in SOT recipients, requiring careful assessment of risks and benefits. If anti-PD-1 therapy is pursued, use of mTOR inhibitors, prophylactic steroids, and donor-derived cell-free DNA monitoring may mitigate the risk of rejection.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":"33 8","pages":"3119-3126"},"PeriodicalIF":2.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10410824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

New insights into delusional infestation. 对妄想感染的新见解。

IF 2.9 4区医学

Journal of Dermatological Treatment Pub Date : 2022-12-01 DOI: 10.1080/09546634.2022.2115835

Jason Reichenberg, Michelle Magid

引用次数: 1